University of Tennessee System President Randy Boyd opened the 10th annual State of the University with remarks and a panel discussion with chancellors and institute leaders, sharing how UT is delivering on its promise by expanding opportunity, strengthening communities and preparing the state for the future.
Pritelivir, a new oral therapy, was significantly more effective against herpes simplex virus (HSV) than a comparator treatment for immunocompromised patients with refractory infections, based on data from 101 individuals.
A long-empty lot off Sam Cooper Boulevard in Binghampton will be completely filled soon.
“Our data demonstrates that SB-216 effectively inhibits PDAC cell growth through inhibiting oncogenic microtubules and mitochondrial function”
A new research paper was published in Volume 13 of Oncoscience on January 28, 2026, titled “Dual targeting of oncogenic microtubules and mitochondria in PDAC.”
“Our data demonstrates that SB-216 effectively inhibits PDAC cell growth through inhibiting oncogenic microtubules and mitochondrial function.”
This 4-part special report examines persistent unmet needs and evolving best practices in anaphylaxis care, drawing on expert discussions from HCPLive, Contemporary Pediatrics, and Patient Care.
Honoring the very best in local technological achievement.
